# K020958: Candela Cbeam Pulsed Dye Laser System

- Pathway: 510(k) (Traditional)
- Applicant: Candela Corp.
- Decided: Jun 21, 2002 after 88 days
- Product code: GEX (Powered Laser Surgical Instrument)
- Device class: 2
- Regulation: 21 CFR 878.4810
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 2 generations back to K000811 (2000). 4 ancestors in all.
231 later devices descend from it; 1 cites it directly.
0 of 236 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K013043: Candela Clearbeam Pulsed Dye Laser, Candela Corp. (2001)
- K013461: Nlite System,Model A00-1025, Icn Photonics, Ltd. (2002) Summary page 1.

## Most influential descendants
- K033331: Candela Cbeam Pulse Dye Laser System (2004), 230 descendants of its own
- K053047: Fraxel SR Laser System (2006), 205 descendants of its own
- K063038: Fraxel Iii SR Laser System and Accessories (2007), 195 descendants of its own
- K071051: Fraxel Iii SR Laser System and Accessories (2007), 194 descendants of its own
- K080915: Fraxel RE:Pair (Fraxel Iii SR) Laser System and Accessories (2008), 187 descendants of its own

## Indications for use
The Candela Cbeam Pulse Dye Laser is indicated for the following uses in: General Surgery: Photocoagulation of benign cutaneous vascular lesion and benign cutaneous lesions. Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesion, such as facial and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and psoriasis. Periorbital wrinkles and the treatment of wrinkles. Gynecology: Photocoagulation of benign cutaneous lesion and benign vascular lesion in gynecology. Podiatry: Treatment of benign cutaneous lesion, such as warts.

Source page: https://510kreport.com/device/K020958
Methodology: https://510kreport.com/methodology